Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPI-62 in ACTH-dependent Cushing's syndrome
NCT05307328Phase 2Completed
- Sponsor
- Sparrow Pharmaceuticals
- Start
- Sep 2022
- Primary completion
- Aug 2025
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 2 trial of clofutriben in Cushing's syndrome, sponsored by Sparrow Pharmaceuticals. Started Sep 2022; status: completed.
02
Drugs
clofutriben
03
Conditions
Cushing's syndrome
Beyond the preview
Go deeper on NCT05307328.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05307328.